血小板与淋巴细胞比率对胃癌预后影响的Meta分析
《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]
- 期数:
- 2020年11期
- 页码:
- 1903-1909
- 栏目:
- 论著（消化·泌尿系肿瘤）
- 出版日期:
- 2020-04-30
文章信息/Info
- Title:
- Prognostic value of platelet-lymphocyte ratio in gastric cancer：A Meta-analysis
- Author(s):
- Jiao Ruonan; Wei Xin; Zhao Si; Wu Xueru; Huang Guangming
- Medical Center for Digestive Diseases，the Second Affiliated Hospital of Nanjing Medical University，Jiangsu Nanjing 210011，China.
- Keywords:
- gastric cancer; platelet; lymphocyte; prognosis; Meta-analysis
- 分类号:
- R735.2
- DOI:
- 10.3969/j.issn.1672-4992.2020.11.022
- 文献标识码:
- A
- 摘要:
- 目的：探讨血小板与淋巴细胞比率(platelet-lymphocyte ratio，PLR)对胃癌患者预后评估的价值。方法：检索PubMed、Medline、Embase、Cochrane Library和中文数据库如中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、万方数字化期刊全文数据库等，纳入关于PLR和胃癌患者预后关系的中英文文献，由2 名研究者独立选择文献和提取数据资料并对纳入文献进行质量评估，采用Review Manager 5.3和Stata 15.1软件进行统计分析。结果：最终共纳入29项符合标准的研究，共计13 696名胃癌患者。Meta分析结果显示治疗前高水平PLR的胃癌患者，其总生存期(overall survival，OS)明显缩短（HR=1.13，95%CI：1.03~1.24，P=0.01），但是与无病生存期(disease-free survival，DFS)(HR=1.19，95%CI：0.79~1.81，P=0.41)和无进展生存期(progression-free survival，PFS)(HR=1.10，95%CI：0.88~1.37，P=0.41)没有明显相关性。结论：治疗前高水平PLR是胃癌患者OS较短的重要临床预后指标，为临床医务工作人员评价胃癌患者的预后提供依据。但是仍需要更多大规模、多中心、更全面的实验研究进行验证。
- Abstract:
- Objective：To investigate the prognostic value of pretreatment platelet-lymphocyte ratio（PLR）in gastric cancer.Methods：An extensive literary search for relevant studies was conducted on PubMed，Medline，Embase，Cochrane Library，China National Knowledge Infrastructure(CNKI)，China Biology Medicine(CBM)，Wanfang Database and so on.We included Chinese and English literature on the relationship between prognosis of patients with PLR and gastric cancer.Study selection，data extraction and quality evaluation were conducted independently by two reviewers.Meta-analysis was conducted by using Review Manager 5.3 and Stata 15.1 software．Results：29 publications including 13 696 gastric cancer patients were collected.The pooled HR showed that elevated PLR was associated with a significantly poorer overall survival(OS)(HR=1.13，95%CI：1.03~1.24，P=0.01).However，there was no obvious prognostic value for disease-free survival(DFS)(HR=1.19，95%CI：0.79~1.81，P=0.41)and progression-free survival(PFS)(HR=1.10，95%CI：0.88~1.37，P=0.41)in patients with gastric cancer.Conclusion：High-level PLR before treatment is an important prognostic clinical standard for patients with gastric cancer，which provides a basis for clinical staff to evaluate the prognosis of patients with gastric cancer.However，more large-scale，multi-center，and more comprehensive experimental studies are still to be validated.
参考文献/References
［1］Ferlay J，Soerjomataram I，Dikshit R，et al.Cancer incidence and mortality worldwide：Sources，methods and major patterns in globocan 2012［J］.Int J Cancer，2015，136(5)：E359-386.
[2]Gu X，Gao XS，Cui M，et al.Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer［J］.Oncotarget，2016，7(31)：49878-49887.
[3]Feng F，Zheng G，Wang Q，et al.Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer［J］.BMC Gastroenterol，2018，18(1)：148.
[4]Templeton AJ，Ace O，Mcnamara MG，et al.Prognostic role of platelet to lymphocyte ratio in solid tumors：A systematic review and meta-analysis［J］.Cancer Epidemiol Biomarkers Prev，2014，23(7)：1204-1212.
[5]Hu G，Liu Q，Ma JY，et al.Prognostic significance of platelet-to-lymphocyte ratio in cholangiocarcinoma：A meta-analysis［J］.Biomed Res Int，2018(2018)：7375169.
[6]Aliustaoglu M，Bilici A，Ustaalioglu BB，et al.The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment［J］.Med Oncol，2010，27(4)：1060-1065.
[7]Hsu JT，Liao CK，Le PH，et al.Prognostic value of the preoperative neutrophil to lymphocyte ratio in resectable gastric cancer［J］.Medicine(Baltimore)，2015，94(39)：e1589.
[8]Chen L，Hao Y，Cong X，et al.Peripheral venous blood platelet-to-lymphocyte ratio(PLR)for predicting the survival of patients with gastric cancer treated with sox or xelox regimen neoadjuvant chemotherapy［J］.Technol Cancer Res Treat，2019(18)：1-13.
[9]Deng Q，He B，Liu X，et al.Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model［J］.J Transl Med，2015(13)：66.
[10]Gong W，Zhao L，Dong Z，et al.After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients［J］.J Clin Lab Anal，2018，32(5)：e22364.
[11]Huang Z，Liu Y，Yang C，et al.Combined neutrophil/platelet/lymphocyte/differentiation score predicts chemosensitivity in advanced gastric cancer［J］.BMC Cancer，2018，18(1)：515.
[12]Jiang N，Deng JY，Liu Y，et al.The role of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after radical resection for gastric cancer［J］.Biomarkers，2014，19(6)：444-451.
[13]Kim EY，Lee JW，Yoo HM，et al.The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio：Which is better as a prognostic factor in gastric cancer［J］?Ann Surg Oncol，2015，22(13)：4363-4370.
[14]Lee JW，Lee MS，Chung IK，et al.Clinical implication of FDG uptake of bone marrow on Pet/Ct in gastric cancer patients with surgical resection［J］.World J Gastroenterol，2017，23(13)：2385-2395.
[15]Lee S，Oh SY，Kim SH，et al.Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy［J］.BMC Cancer，2013(13)：350.
[16]Lian L，Xia YY，Zhou C，et al.Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer［J］.Cancer Biomark，2015，15(6)：899-907.
[17]Liu X，Sun X，Liu J，et al.Preoperative c-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer［J］.Transl Oncol，2015，8(4)：339-345.
[18]Ramos-Esquivel A，Cordero-Garcia E，Brenes-Redondo D，et al.The neutrophil-lymphocyte ratio is an independent prognostic factor for overall survival in hispanic patients with gastric adenocarcinoma［J］.J Gastrointest Cancer，2018.doi：10.1007/s12029-018-0134-z.
[19]Song S，Li C，Li S，et al.Derived neutrophil to lymphocyte ratio and monocyte to lymphocyte ratio may be better biomarkers for predicting overall survival of patients with advanced gastric cancer［J］.Onco Targets Ther，2017(10)：3145-3154.
[20]Sun KY，Xu JB，Chen SL，et al.Novel immunological and nutritional-based prognostic index for gastric cancer［J］.World J Gastroenterol，2015，21(19)：5961-5971.
[21]Sun X，Wang J，Liu J，et al.Albumin concentrations plus neutrophil lymphocyte ratios for predicting overall survival after curative resection for gastric cancer［J］.Onco Targets Ther，2016(9)：4661-4669.
[22]Toyokawa T，Muguruma K，Tamura T，et al.Comparison of the prognostic impact and combination of preoperative inflammation-based and/or nutritional markers in patients with stage II gastric cancer［J］.Oncotarget，2018，9(50)：29351-29364.
[23]Wang J，Qu J，Li Z，et al.Pretreatment platelet-to-lymphocyte ratio is associated with the response to first-line chemotherapy and survival in patients with metastatic gastric cancer［J］.J Clin Lab Anal，2018，32(1)：e22185.
[24]Wang K，Diao F，Ye Z，et al.Prognostic value of systemic immune-inflammation index in patients with gastric cancer［J］.Chin J Cancer，2017，36(1)：75.
[25]Zhang LX，Wei ZJ，Xu AM，et al.Can the neutrophil-lymphocyte ratio and platelet-lymphocyte ratio be beneficial in predicting lymph node metastasis and promising prognostic markers of gastric cancer patients? Tumor maker retrospective study［J］.Int J Surg，2018(56)：320-327.
[26]Zhang Y，Lu JJ，Du YP，et al.Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer［J］.Medicine(Baltimore)，2018，97(12)：e0144.
[27]Zhu GS，Tian SB，Wang H，et al.Preoperative neutrophil lymphocyte ratio and platelet lymphocyte ratio cannot predict lymph node metastasis and prognosis in patients with early gastric cancer：A single institution investigation in China［J］.Curr Med Sci，2018，38(1)：78-84.
[28]LIU YT，YANG C，LI XY，et al.The infulence of peripheral blood NLR-PLR combined paratermeter on the first-line chemotherapy outcome in advanced gastric cancer patients［J］.Modern Digestion & Intervention，2017，22(5)：628-634.［刘彦潭，杨晨，李小茵，等.外周血NLR-PLR组合参数对于晚期胃癌一线化疗疗效的影响［J］.现代消化及介入诊疗，2017，22(5)：628-634.］
[29]WANG G，ZHANG HH，JIAO HB.Clinical significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio on the prognosis of patients for gastric cancer［J］.Modern Oncology，2017，25(24)：4014-4017.［王刚，张宏亨，焦宏博.中性粒细胞计数比率与血小板计数比率对胃癌患者预后的临床意义［J］.现代肿瘤医学，2017，25(24)：4014-4017.］
[30]YANG QS，HU ZY，ZHU Y，et al.Study on the relationship between peripheral lymphocyte-to-white blood cell ratio and clinical pathology and prognosis among gastric cancer patients［J］.Chin J Clin Healthc，2018，21(6)：739-744.［杨群树，胡正宇，朱勇，等.胃癌患者外周血中淋巴细胞/白细胞与临床病理及预后问的关系［J］.中国临床保健杂志，2018，21(6)：739-744.］
[31]ZHANG FC，JIANG Y，LIU ZN，et al.Prognostic significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in systemic inflammation-related indicators in gastric cancer patients after radical resection［J］.Practical Oncology Journal，2019，33(1)：34-39.［张凤春，江莺，刘照南，等.系统性炎症相关指标中性粒细胞/淋巴细胞比值及血小板/淋巴细胞比值在根治性切除术后的胃癌患者的预后意义［J］.实用肿瘤学杂志，2019，33(1)：34-39.］
[32]ZHANG MH，XU GR，XU JH，et al.Prognostic significance of reoperative platelet-lymphocyte ratio in patients with gastric cancer［J］.Chinese Clinical Oncology，2016，21(10)：913-918.［张明辉，徐光如，徐金华，等.胃癌患者术前血小板/淋 巴细胞比值的预后意义［J］.临床肿瘤学杂志，2016，21(10)：913-918.］
[33]ZHAO ZZ，WANG JM，YING W，et al.Evaluation value of preoperative peripheral blood NLR and PLR on prognosis of gastric cancer［J］.Journal of Tianjin Medical University，2018，24(1)：50-54.［赵忠治，王金淼，颖魏，等.术前外周血NLR与PLR对胃癌预后的评估价值［J］.天津医科大学学报，2018，24(1)：50-54.］
[34]Zhou X，Xu L，Huang Z，et al.The hematologic markers as prognostic factors in patients with resectable gastric cancer［J］.Cancer Biomark，2016，17(3)：359-367.
[35]Shi H，Jiang Y，Cao H，et al.Nomogram based on systemic immune-inflammation index to predict overall survival in gastric cancer patients［J］.Dis Markers，2018(2018)：1787424.
[36]Brimnes MK，Vangsted AJ，Knudsen LM，et al.Increased level of both CD4+FOXP3+regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma［J］.Scand J Immunol，2010，72(6)：540-547.
[37]Rachidi S，Metelli A，Riesenberg B，et al.Platelets subvert T cell immunity against cancer via GARP-TGFβ axis［J］.Sci Immunol，2017，2(11)：eaai7911.
[38]Contursi A，Grande R，Dovizio M，et al.Platelets in cancer development and diagnosis［J］.Biochem Soc Trans，2018，46(6)：1517-1527.
[39]Carvalho-Tavares J，Hickey MJ，Hutchison J，et al.A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature［J］.Circ Res，2000，87(12)：1141-1148.
[40]Farzianpour F，Rahimi Foroushani A，Shahidi Sadeghi N，et al.Relationship between' patient's rights charter' and patients' satisfaction in gynecological hospitals［J］.BMC Health Serv Res，2016(16)：476.
[41]Quigley DA，Kristensen V.Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells［J］.Mol Oncol，2015，9(10)：2054-2062.
[42]Kollmann D，Ignatova D，Jedamzik J，et al.Expression of programmed cell death protein 1 by tumor-infiltrating lymphocytes and tumor cells is associated with advanced tumor stage in patients with esophageal adenocarcinoma［J］.Ann Surg Oncol，2017，24(9)：2698-2706.
[43]Roma-Rodrigues C，Mendes R，Baptista PV，et al.Targeting tumor microenvironment for cancer therapy［J］.Int J Mol Sci，2019，20(4)：840.
备注/Memo
- 备注/Memo:
- 江苏省社会发展面上项目（编号：BE2016799）
